BioCentury | Oct 19, 2019
Finance

Achillion’s journey to $1 billion

...of HCV regimen JNJ-4178, which combined the biotech’s odalasvir with the pharma’s AL-335 and Olysio simeprevir...
BioCentury | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

...of HCV regimen JNJ-4178, which combined the biotech’s odalasvir with the pharma’s AL-335 and Olysio simeprevir...
BioCentury | Jun 1, 2018
Clinical News

Gilead's Epclusa approved in China for HCV

...Bristol-Myers Squibb Co. (NYSE:BMY); Viekirax ombitasvir/paritaprevir/ritonavir and Exviera dasabuvir from AbbVie Inc. (NYSE:ABBV); and Olysio simeprevir...
BioCentury | May 30, 2018
Company News

Gilead's Epclusa approved in China for HCV

...Bristol-Myers Squibb Co. (NYSE:BMY); Viekirax ombitasvir/paritaprevir/ritonavir and Exviera dasabuvir from AbbVie Inc. (NYSE:ABBV); and Olysio simeprevir...
BioCentury | Dec 2, 2017
Strategy

Opening the gates in China

...Sunvepra asunaprevir from Bristol-Myers Squibb Co.; Viekirax ombitasvir/paritaprevir/ritonavir and Exviera dasabuvir from AbbVie Inc.; Olysio simeprevir...
...in combination to treat HCV genotype 1b in patients with or without cirrhosis. In August Olysio...
...interferon to treat genotypes 1-6. J&J did not provide details on the genotypes for which Olysio...
BioCentury | Oct 27, 2017
Company News

Arcturus, JNJ to develop nucleic acids to treat HBV

...Therapeutics Inc. , San Diego, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Chemistry Allison Johnson ACH-3102 AL-335 JNJ-4178 LUNAR-HBV simeprevir Achillion...
BioCentury | Sep 15, 2017
Company News

J&J drops Achillion HCV deal

...JNJ-4178 is an oral combination of Achillion's odalasvir (ACH-3102) plus J&J's AL-335 and Olysio simeprevir...
...is a second-generation HCV NS5A protein inhibitor. AL-335 is an HCV NS5B polymerase inhibitor and Olysio...
BioCentury | Sep 12, 2017
Company News

Achillion down after J&J drops HCV compound

...is an oral combination of Achillion's odalasvir ( ACH-3102 ) plus J&J's AL-335 and Olysio simeprevir...
...is a second-generation HCV NS5A protein inhibitor. AL-335 is an HCV NS5B polymerase inhibitor and Olysio...
BioCentury | Apr 28, 2017
Politics, Policy & Law

Access and innovation in Japan

...HCV 12/19/16 Daklinza daclatasvir HCV 7/4/14 Sunvepra asunaprevir HCV 7/4/14 Johnson & Johnson (NYSE:JNJ) Sovriad simeprevir...
BioCentury | Jan 11, 2017
Distillery Therapeutics

Infectious disease

...IC 50 values of 0.33-3.17 μM. Also in the assay, cajanine plus Daklinza daclatasvir, Olysio simeprevir...
...for HCV. Medivir AB and Johnson & Johnson market the HCV NS3/4A protease complex inhibitor Olysio...
...Medical College, Beijing, China email: lizhuorong@imb.pumc.edu.cn CONTACT: Zong-Gen Peng, same affiliation as above email: pengzonggen@imb.pumc.edu.cn Steven Hochhauser Daklinza Olysio Sovaldi Chinese...
Items per page:
1 - 10 of 308